Lumavita
Biopharmaceutical company developing and commercialising of novel anti-infectives for women's health
About Lumavita
Lumavita AG operated as a clinical-stage biopharmaceutical company with a focus on developing treatments for women's health, specifically targeting gynecological infections. Founded in August 2008 in Basel, Switzerland, the company was established by Dr. Cees Winnips, who served as the Chief Scientific Officer, leveraging his extensive background in pharmaceutical development, including anti-infective drugs. The formation of Lumavita emerged from Shogoo Pharmaceuticals, a Japanese biopharmaceutical company that was winding down its operations; Lumavita was created to continue the work of Shogoo's Swiss subsidiary.
The company's business model centered on the global development and commercialization of its proprietary product portfolio. Its lead product was FemiFect® (pentamycin), a broad-spectrum antibiotic designed to treat vaginitis by targeting its three main causes: bacteria, fungi, and protozoa. FemiFect was already approved in Switzerland at the time of the company's launch, and Lumavita aimed to establish a commercial partnering network to distribute the product in over 100 countries. Lumavita's pipeline also included LMV-601 (previously SPK-601), a first-in-class antiviral treatment for infections caused by the Human Papilloma Virus (HPV). The company's strategy involved advancing these products through clinical trials, gaining marketing approvals, and launching them in key markets.
Lumavita secured significant funding to support its operations. In September 2008, it announced a Series A financing round of CHF 18 million (€11 million), led by investors Atlas Venture, BB Biotech Ventures, and BioMedInvest. This was followed by an extension in June 2009, which brought the total raised in the financing round to CHF 24 million, with HealthCap joining as a new investor alongside existing investor Endeavour Vision. At its inception, Nicholas Benedict, who had a 17-year career with leadership roles at Roche and Novartis, was appointed as CEO. According to market analysis platforms, the company is now considered deadpooled.
Source: Dealroom company dataNews
Open roles
Lumavita in the Basel ecosystem
The Lumavita office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
HealthCap
Endeavour Vision
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Lumavita on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lumavita on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

